At the forefront of therapies for rare and orphan diseasesTM
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
05/26/2015 Amicus Therapeutics' Fabry Monotherapy Granted Accelerated Assessment by European Regulators
05/05/2015 Amicus Therapeutics Announces First Quarter 2015 Financial Results and Corporate Updates
05/01/2015 Amicus Therapeutics to Announce First Quarter 2015 Financial Results on May 5, 2015
Amicus Therapeutics CEO: Driving science to a cure
John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC's Jim Cramer.

Click Here to Read the Article

Copyright © 2015 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy